|Day's Range||54.41 - 54.49|
|52 Week Range||53.56 - 56.26|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.12%|
European UNISEC Co-Sponsored Trial Meets Both Primary Endpoints NESS ZIONA, Israel , July 20, 2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), and the UNISEC consortium today ...
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, today signed an agreement to lease approximately 1800m2 in the Jerusalem BioPark (JBP), located in the Ein Kerem Hadassah campus, next to Hadassah University Hospitals and Hebrew University's Medical School. M-001 is designed to provide protection against current and future seasonal and pandemic flu strains. Planning and design of the facility by a leading engineering company has begun, and while construction will begin soon, the agreement calls for BiondVax to begin lease payments in October 2018.
First Ascent Asset Management is a newcomer in the ETF strategist space, building two series of portfolios for advisors: one using only ETFs, the other combining ETFs with actively managed mutual funds.